interrogated for clinical or pathologic diagnosis. For molecular validation, FFPE placental blocks were compared to matched frozen samples from 20 patients with uncomplicated pregnancies undergoing scheduled cesarean delivery. RNA was compared on the measurements of RNA quality (RNA integrity numbers (RIN) using an Agilent Bioanalyzer), and quantitative Real-Time PCR (qPCR) expression of house-keeping genes. RESULTS: Our database has over 1000 pregnancies coded for clinical diagnosis and linked to stored FFPE blocks. FFPE samples in the database can now be used for targeted gene expression studies. RNA harvested from FFPE tissues is of sufficient quality for downstream applications (RIN of 2.0). Housekeeping genes (YWHAZ, CYC1, and TOP1) have been identified that are expressed in FFPE tissue at levels comparable to matched fresh frozen samples from the same placenta (n¼20, p>0.05, see graph). CONCLUSION: We have successfully established a platform for placental analysis studies that links clinicopathological data and molecular gene expression. This pipeline will increase our understanding of obstetrical diseases and their impact on child health, with the ultimate goal of identifying placental biomarkers of diseases.
922 Leveraging whole genome sequencing in noninvasive prenatal screening: Prader-Willi syndrome due to uniparental disomy Susan E. Hancock, Albert Lee, Kevin Haas, Carrie Haverty Counsyl, Inc, South San Francisco, CA OBJECTIVE: Noninvasive prenatal screening (NIPS) has been rapidly incorporated into clinical care since 2011. Initially replacing traditional aneuploidy screening in high-risk populations, NIPS is becoming a first-line screening approach in the general obstetric population for the common aneuploidies of chromosomes 21, 18 and 13. With a whole genome sequencing (WGS) approach to NIPS, detection of aneuploidy of all autosomes is possible, providing additional clinical benefit. Here we describe a case of Prader Willi syndrome (PWS) with trisomy of chromosome 15 clearly indicated by analysis with a WGS-based NIPS. STUDY DESIGN: A 26 year-old patient with a singleton pregnancy and no identified risk factors underwent WGS-based NIPS using Counsyl Prelude at 10 weeks 6 days gestation. The Prelude analysis pipeline calculates z-scores for autosomes, allosomes, and microdeletions, but results were only issued for the requested chromosomes: 21,18,13, X and Y.
RESULTS:
Results were negative for the common trisomies (21, 18, 13) and positive for an increased risk for monosomy X. The patient did not pursue prenatal diagnosis. Postnatally, the newborn was diagnosed with PWS due to maternal uniparental disomy (UPD) of chromosome 15. A review of NIPS WGS data showed a clear signal for trisomy 15, indicating that trisomy 15 was present in the placenta. Trisomy rescue is the expected mechanism that resulted in PWS due to maternal UPD in the neonate. CONCLUSION: NIPS is well accepted as a superior screening method for identifying common trisomies; however, the benefit of reporting aneuploidy for other autosomes is not yet well-defined. This case presents the potential benefit of reporting autosomal aneuploidies beyond 21, 18, and 13. Such a result alerts the clinician and patient to the possibility of a non-aneuploid genetic disorder and prompts discussion of the condition and specialized testing. As UPD is not detectable via standard amniocentesis karyotype, an aneuploid NIPS result for an imprinted chromosome signals the need for additional testing to capture UPD. WGS-based NIPS expanded to report on any aneuploidy can identify more pregnancies with genetic syndromes by identifying those pregnancies at risk for UPD disorders.
923 Avoiding trade-offs: Clinical experience for noninvasive prenatal screen with low no-call rate and high accuracy OBJECTIVE: Noninvasive Prenatal Screening (NIPS) via cell-free DNA analysis (cfDNA) has been rapidly incorporated into prenatal care since 2011. The Counsyl Prelude Prenatal Screen utilizes a widely reported whole genome sequencing (WGS) approach to NIPS. Here we describe the clinical experience of offering Prelude in our laboratory. STUDY DESIGN: We retrospectively analyzed results from 58,028 patients who underwent NIPS over a nine month period to assess clinical performance for identifying Trisomy 21, Trisomy 18, and Trisomy 13 in singleton pregnancies. We sought pregnancy outcomes for all positive results and 10% of negative results. Voluntarily reported false negatives were also included. RESULTS: The patient cohort included average-risk (41%, n¼23,735) and high-risk patients (59%, n¼34,293). Median maternal age was 34 years (interquartile range (IQR): 29-37 years). Median gestational age was 12.4 weeks (IQR: 11.3-13.7 weeks). Unlike several NIPS offerings that do not provide a result when fetal fraction (FF) is below a specified threshold, Prelude does not fail samples solely based on fetal fraction. As such, the screen yielded a result for 99.9% of patients; no result was issued for 0.1% of cases (n¼59) due to technical reasons. Median turnaround time was three days (IQR: 2-4 days). 572 cases (1%) screened positive ("aneuploidy detected" or "aneuploidy suspected") with 362 positive for Trisomy 21, 142 positive for Trisomy 18, and 68 positive for Trisomy 13. "Aneuploidy suspected" reports accounted for 6.5% of positive results (n¼37), 0.06% of the total cohort.
Informative African American patients were significantly higher for all serum analytes tested. In addition, UtAD-PI was significantly increased in this group. Asian patients demonstrated significantly higher Inhibin while Asian Indian patients were significantly higher for both Inhibin and PlGF. Hispanic patients were low for Free beta hCG and AFP but were slightly higher for Inhibin and UtAD-PI. CONCLUSION: All first trimester biochemical markers for Early Onset Preeclampsia and Down syndrome screening vary based on maternal race/ethnicity. UtAD-PI similarly varies based on race/ethnicity but no statistically significant change in MAP was observed in any ethnic group. Adjustments for each marker except MAP are indicated.
925 Non-reportable cell-free DNA: patient preferences, utility of repeat draw, and outcomes A NR result for a microdeletion but negative testing for above chromosomes were excluded. The primary outcome was aneuploidy or microarray abnormality on prenatal or postnatal genetic testing. Secondary outcomes evaluated were maternal characteristics, testing laboratory and methodology, and pregnancy and neonatal outcomes. Statistical analysis was performed utilizing Student's t-test and Fisher's exact test. RESULTS: Forty-six patients had NR cfDNA results, of which 31 (67.4%) had low fetal fraction (FF). Mean maternal age was 34.2 AE 4.9 years, and median gestational age at initial blood draw was 10.4 weeks (IQR 10.1 e 11.6). Median body mass index (BMI) was 28.1 kg/m 2 (IQR 23.6 e 32.6), and 43% were obese. Of these patients, 6 (13%) chose diagnostic testing, 38 (82.7%) opted for a repeat blood draw, and 2 (4.3%) declined additional testing. On repeat cfDNA sampling, 15 (39.5%) had a NR result and 23 (60.5%) had a reported result. Maternal age and BMI did not significantly differ in patients with a persistent NR result (p > 0.05); they were more likely to have maternal comorbidities (p ¼ 0.04) and a FF < 4% at time of initial blood draw (p ¼ 0.05). Obtaining a reportable or NR result on redraw did not differ by laboratory or testing method (p > 0.05). Patients with a repeat NR result were significantly more likely to undergo diagnostic testing (66.7% vs 4.3%, p < 0.01), which yielded an aneuploidy result in 20% of patients. Pregnancy outcomes did not significantly differ in patients with a repeat NR result (p > 0.05), detailed in the table. CONCLUSION: Almost half of repeat testing following a NR cfDNA result will again be NR. Repeat NR result is more likely in patients with medical comorbidities and FF < 4% at initial blood draw. It is associated with a 20% incidence of aneuploidy but not associated with an increased risk of adverse pregnancy outcomes. These test characteristics are important to consider when counseling patients on management following an initial NR cfDNA result. 
